^
    13d
    LUCIDA_2: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, FutureChem | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    13d
    LUCIDA: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application (clinicaltrials.gov)
    P1/2, N=26, Recruiting, FutureChem | Phase classification: P2a --> P1/2 | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    FOLH1 positive
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    1year
    Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [F]DCFPyL and [Ga]PSMA-11. (PubMed, Biochem Biophys Res Commun)
    All three agents showed high uptake in tumor tissue on autoradiography, and PSMA expression was confirmed by immunohistochemistry. Thus, [F]DCFPyL or [Ga]PSMA-11 can be used as a PET imaging agent to monitor [Lu]ludotadipep therapy in prostate cancer patients.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    [177Lu]ludotadipep (177 Lu-FC705)